Skip to main content
LLM 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Session III: AML and MDS

Debate: All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax - YES

Wednesday, October 18, 2023
2:45 PM - 3:00 PM ET
Location: Metropolitan East

    Debate Speaker(s)

  • Pinkal Desai, MD

    Weill Cornell Medicine
    New York, New York, United States